Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes.
BACKGROUND
Although fatty liver and insulin resistance are known to be associated, the relationship between the two in the development of type 2 diabetes mellitus (T2DM) is unclear.


OBJECTIVE
We investigated the 5-yr risk of developing T2DM in individuals diagnosed with fatty liver using ultrasound and stratified by insulin sensitivity using quartiles of fasting insulin concentration.


METHODS
We examined the clinical and laboratory data of 11,091 Koreans who had a medical evaluation including fasting insulin concentration and abdominal ultrasound at baseline and had a follow-up after 5 yr.


RESULTS
At baseline, 27% of the population had fatty liver. Almost half (47%) of the individuals with fatty liver had baseline insulin concentration in the highest quartile compared with 17% in those without fatty liver (P < 0.001). Regardless of baseline insulin concentration, individuals with fatty liver had significantly (P < 0.001) more baseline clinical and metabolic abnormalities, including higher glucose and triglyceride concentration and lower high-density lipoprotein cholesterol concentration. In addition, regardless of baseline insulin concentration, individuals with fatty liver had a significantly increased risk for incident T2DM compared with those without fatty liver [crude odds ratio, 5.05 (95% confidence interval, 2.08-12.29) in the lowest insulin quartile and 6.34 (3.58-11.21) in the highest quartile]. In individuals in the highest insulin quartile, the odds ratio for developing T2DM remained significant even after multivariate adjustment including baseline glucose concentration [2.42 (1.23-4.75)].


CONCLUSIONS
Although associated with insulin resistance, fatty liver diagnosed by ultrasound appears to independently increase the risk of T2DM.
Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea. kcmd.sung@samsung.com
Ki-Chul
KC
Sung
Sun H
SH
Kim
D000328:Adult; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D005234:Fatty Liver / Q000150:complications* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
D007328:Insulin
Lancet. 1992 Oct 17;340(8825):925-9
1357346
J Gastroenterol Hepatol. 2007 Jul;22(7):1086-91
17608855
Endocr Rev. 2008 Dec;29(7):939-60
18723451
Diabetes Care. 2007 Oct;30(10):2690-4
17623829
Diabetes Care. 2004 Aug;27(8):1998-2002
15277430
J Gastroenterol Hepatol. 2010 Feb;25(2):352-6
19817963
Diabetes. 2002 Apr;51(4):1131-7
11916936
Gastroenterology. 2002 Sep;123(3):745-50
12198701
Diabetes. 1988 Dec;37(12):1595-607
3056758
Am J Gastroenterol. 2010 Nov;105(11):2389-95
20628364
Diabet Med. 2008 Apr;25(4):476-81
18346164
Diabetes Care. 2010 Jan;33(1):200-2
19808927
Diabetes Care. 2007 Aug;30(8):2113-8
17475935
Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15430-5
19706383
Atherosclerosis. 2010 Jan;208(1):240-5
19656511